{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:07:17Z","timestamp":1790298437049,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T00:00:00Z","timestamp":1510358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00228-017-2366-4","type":"journal-article","created":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T10:05:14Z","timestamp":1510394714000},"page":"219-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-6423","authenticated-orcid":false,"given":"Irene","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickard E.","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,11]]},"reference":[{"issue":"1","key":"2366_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13311-012-0163-4","volume":"10","author":"CA McGraw","year":"2013","unstructured":"McGraw CA, Lublin FD (2013) Interferon beta and glatiramer acetate therapy. Neurotherapeutics : J Am Soc Experimental NeuroTherapeutics 10(1):2\u201318. https:\/\/doi.org\/10.1007\/s13311-012-0163-4","journal-title":"Neurotherapeutics : J Am Soc Experimental NeuroTherapeutics"},{"key":"2366_CR2","unstructured":"Pollack A (2013) 3rd Oral Drug to Treat MS Is Approved by the F.D.A. The New Your Times. [cited 2017 Jun 9]; Available from: http:\/\/www.nytimes.com\/2013\/03\/28\/business\/3rd-oral-drug-to-treat-ms-is-approved-by-the-fda.html"},{"issue":"2","key":"2366_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/dtb.2012.02.0086","volume":"50","author":"Fingolimod for multiple sclerosis","year":"2012","unstructured":"Fingolimod for multiple sclerosis (2012) Drug Ther Bull 50(2):18\u201320. https:\/\/doi.org\/10.1136\/dtb.2012.02.0086","journal-title":"Drug Ther Bull"},{"issue":"7","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/dtb.2014.7.0267","volume":"52","author":"Teriflunomide for multiple sclerosis","year":"2014","unstructured":"Teriflunomide for multiple sclerosis (2014) Drug Ther Bull 52(7):81\u201384. https:\/\/doi.org\/10.1136\/dtb.2014.7.0267","journal-title":"Drug Ther Bull"},{"issue":"9","key":"2366_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/dtb.2014.9.0279","volume":"52","author":"Dimethyl fumarate for relapsing-remitting multiple sclerosis","year":"2014","unstructured":"Dimethyl fumarate for relapsing-remitting multiple sclerosis (2014) Drug Ther Bull 52(9):105\u2013108. https:\/\/doi.org\/10.1136\/dtb.2014.9.0279","journal-title":"Drug Ther Bull"},{"key":"2366_CR6","doi-asserted-by":"publisher","first-page":"i3518","DOI":"10.1136\/bmj.i3518","volume":"354","author":"DM Wingerchuk","year":"2016","unstructured":"Wingerchuk DM, Weinshenker BG (2016) Disease modifying therapies for relapsing multiple sclerosis. BMJ (Clinical Res ed) 354:i3518. https:\/\/doi.org\/10.1136\/bmj.i3518","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"issue":"6","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, Axelsson M, Malmestrom C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950\u2013958. https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Ann Neurol"},{"issue":"7","key":"2366_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B (2011) Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495\u2013506. https:\/\/doi.org\/10.1038\/nrd3501","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","volume":"19","author":"C Nordon","year":"2016","unstructured":"Nordon C, Karcher H, Groenwold RH, Ankarfeldt MZ, Pichler F, Chevrou-Severac H, Rossignol M, Abbe A, Abenhaim L (2016) The \u201cefficacy-effectiveness gap\u201d: historical background and current conceptualization. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 19(1):75\u201381. https:\/\/doi.org\/10.1016\/j.jval.2015.09.2938","journal-title":"Value Health : J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"4","key":"2366_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, Ham RT, de Boer A, Hillege H, Klungel O, Goettsch W (2017) Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 20(4):520\u2013532. https:\/\/doi.org\/10.1016\/j.jval.2016.12.003","journal-title":"Value Health : J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"2366_CR12","unstructured":"TLV | Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket | TLV [Internet]. Tlv.se. 2017 [cited 2017 Jun 9];Available from: https:\/\/www.tlv.se\/"},{"issue":"12","key":"2366_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa1114287","journal-title":"N Engl J Med"},{"issue":"12","key":"2366_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087\u20131097. https:\/\/doi.org\/10.1056\/NEJMoa1206328","journal-title":"N Engl J Med"},{"issue":"5","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/fampra\/cmt033","volume":"30","author":"P Wandell","year":"2013","unstructured":"Wandell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G (2013) Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011. Fam Pract 30(5):506\u2013513. https:\/\/doi.org\/10.1093\/fampra\/cmt033","journal-title":"Fam Pract"},{"issue":"5","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/ecco-jcc\/jjv243","volume":"10","author":"T Cars","year":"2016","unstructured":"Cars T, Wettermark B, Lofberg R, Eriksson I, Sundstrom J, Lordal M (2016) Healthcare utilisation and drug treatment in a large cohort of patients with inflammatory bowel disease. J Crohn\u2019s Colitis 10(5):556\u2013565. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv243","journal-title":"J Crohn\u2019s Colitis"},{"key":"2366_CR17","doi-asserted-by":"publisher","unstructured":"Forslund T, Wettermark B, Andersen M, Hjemdahl P (2017) Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology doi: https:\/\/doi.org\/10.1093\/europace\/euw416","DOI":"10.1093\/europace\/euw416"},{"key":"2366_CR18","unstructured":"\u00c5tg\u00e4rdskoder (KV\u00c5) [Internet]. Socialstyrelsen.se. 2017 [cited 2017 Jun 9];Available from: http:\/\/www.socialstyrelsen.se\/klassificeringochkoder\/atgardskoderkva . http:\/\/www.socialstyrelsen.se\/klassificeringochkoder\/atgardskoderkva"},{"issue":"7","key":"2366_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish prescribed drug register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726\u2013735. https:\/\/doi.org\/10.1002\/pds.1294","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2366_CR20","unstructured":"Average Number of Drug Classes Used by Seniors on Public Drug Programs [Internet]. Indicatorlibrary.cihi.ca . 2017 [cited 2017 Jun 9];Available from: http:\/\/indicatorlibrary.cihi.ca\/display\/HSPIL\/Average+Number+of+Drug+Classes+Used+by+Seniors+on+Public+Drug+Programs"},{"issue":"4","key":"2366_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV (2010) Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 13(4):618\u2013625. https:\/\/doi.org\/10.3111\/13696998.2010.523670","journal-title":"J Med Econ"},{"issue":"2","key":"2366_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/wnl.0000000000002832","volume":"87","author":"P Flon de","year":"2016","unstructured":"de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A (2016) Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 87(2):141\u2013147. https:\/\/doi.org\/10.1212\/wnl.0000000000002832","journal-title":"Neurology"},{"key":"2366_CR23","doi-asserted-by":"publisher","unstructured":"de Flon P, Laurell K, Soderstrom L, Gunnarsson M, Svenningsson A (2016) Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Multiple sclerosis (Houndmills, Basingstoke, England):1352458516676643. doi: https:\/\/doi.org\/10.1177\/1352458516676643","DOI":"10.1177\/1352458516676643"},{"issue":"2","key":"2366_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00415-015-7979-x","volume":"263","author":"J Salzer","year":"2016","unstructured":"Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A (2016) Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 263(2):322\u2013326. https:\/\/doi.org\/10.1007\/s00415-015-7979-x","journal-title":"J Neurol"},{"issue":"20","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/wnl.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, Islam-Jakobsson P, Malmestrom C, Axelsson M, Vagberg M, Sundstrom P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074\u20132081. https:\/\/doi.org\/10.1212\/wnl.0000000000003331","journal-title":"Neurology"},{"issue":"7","key":"2366_CR26","doi-asserted-by":"publisher","first-page":"A400","DOI":"10.1016\/j.jval.2014.08.912","volume":"17","author":"N Bergvall","year":"2014","unstructured":"Bergvall N, Lahoz R, Nazareth T, Korn JR (2014) Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of us open-source pharmacy data. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 17(7):A400\u2013A401. https:\/\/doi.org\/10.1016\/j.jval.2014.08.912","journal-title":"Value Health : J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"2366_CR27","unstructured":"Polson M, Lord T, Ko J, Evangelatos T, Herrera V (2016) Real world comparison of patient adherence and persistence to fingolimod vs. dimethyl fumarate (P3.101). Neurology 86 (16 Supplement). http:\/\/www.neurology.org\/content\/86\/16_Supplement\/P3.101"},{"issue":"8","key":"2366_CR28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.18553\/jmcp.2017.23.8.844","volume":"23","author":"KM Johnson","year":"2017","unstructured":"Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V (2017) Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Managed Care Specialty Pharmacy 23(8):844\u2013852","journal-title":"J Managed Care Specialty Pharmacy"},{"key":"2366_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.msard.2016.08.002","volume":"10","author":"CM Hersh","year":"2016","unstructured":"Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D (2016) Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis Related Disorders 10:44\u201352. https:\/\/doi.org\/10.1016\/j.msard.2016.08.002","journal-title":"Multiple Sclerosis Related Disorders"},{"issue":"1","key":"2366_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12883-016-0698-9","volume":"16","author":"T Nazareth","year":"2016","unstructured":"Nazareth T, Friedman HS, Navaratnam P, Herriott DA, Ko JJ, Barr P, Sasane R (2016) Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review. BMC Neurol 16(1):187. https:\/\/doi.org\/10.1186\/s12883-016-0698-9","journal-title":"BMC Neurol"},{"key":"2366_CR31","doi-asserted-by":"crossref","unstructured":"Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E (2017) Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Multiple Sclerosis Journal\u2013Experimental, Translational and Clinical 3 (3):2055217317725102","DOI":"10.1177\/2055217317725102"},{"key":"2366_CR32","doi-asserted-by":"publisher","unstructured":"Smoot K, Spinelli KJ, Stuchiner T, Lucas L, Chen C, Grote L, Baraban E, Kresa-Reahl K, Cohan S (2017) Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Multiple sclerosis (Houndmills, Basingstoke, England):1352458517709956. doi: https:\/\/doi.org\/10.1177\/1352458517709956","DOI":"10.1177\/1352458517709956"},{"key":"2366_CR33","unstructured":"Individdata om rekvisitionsl\u00e4kemedel: uppf\u00f6ljning, dokumentation och informatik. Nationella l\u00e4kemedelsstrategin, omr\u00e5de 6.4, slutrapport (2015). Sveriges Kommuner och Landsting, Stockholm"},{"issue":"8","key":"2366_CR34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0895-4356(94)00234-H","volume":"48","author":"R Tamblyn","year":"1995","unstructured":"Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999\u20131009","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2366_CR35","first-page":"67","volume":"10","author":"AR Levy","year":"2003","unstructured":"Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D (2003) Coding accuracy of administrative drug claims in the Ontario drug benefit database. Canadian J Clinical Pharmacology=J Canadien de Pharmacologie Clinique 10(2):67\u201371","journal-title":"Canadian J Clinical Pharmacology=J Canadien de Pharmacologie Clinique"},{"issue":"4","key":"2366_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323\u2013337. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.10.012","journal-title":"J Clin Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2366-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T21:31:09Z","timestamp":1570311069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2366-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,11]]}}}